1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP
  1. Beenthere2Hippie
    WASHINGTON — The price may be high but so is demand. A new $1,000-per-pill drug has become the treatment of choice for Americans with hepatitis C, a liver-wasting disease that affects more than 3 million.

    Even with insurers reluctant to pay, Sovaldi prescriptions have eclipsed those for all other hepatitis C pills combined in a matter of months, new data from IMS Health indicate. The promise of a real cure, with fewer nasty side effects, has prompted thousands to get treated.

    But clinical and commercial successes are also triggering scrutiny for the drug's manufacturer, California-based Gilead Sciences Inc., which just reported second-quarter profits of $3.66 billion, or 56 percent.

    Two senators have unearthed documents that suggest the initial developers of Sovaldi considered pricing it at less than half as much. The health insurance industry is publicly scolding Gilead, and state Medicaid programs are pushing back.

    The repercussions go beyond one drug and one disease. A number of promising cancer medications near approval could be drawn into the storm over costs.

    "You can't put too fine a point on the sort of moral dilemma that we have here," said Michael Kleinrock, director of the IMS Institute, which studies prescription drug trends. "This is something that the research-based pharmaceutical industry reaches for all the time: a cure. But when they achieve one, can we afford it?"

    New data from IMS Health, the parent company of the institute, illustrate Sovaldi's impact since its December debut:

    —The number of pharmacy prescriptions for all hepatitis C pills has soared, highlighting demand. In May, more than 48,000 prescriptions were filled for four such medications, with Sovaldi accounting for three-fourths of the total. Compare that to prescriptions for May 2013, before Sovaldi became available, which totaled about 6,200.

    —In Sovaldi's first 30 weeks on the market, 62,000 new patients tried the drug, nearly three times as many as had tried an earlier medication that showed promise. That makes Sovaldi the most successful launch for any hepatitis C drug. Gilead expects to have a successor soon that will make treatment easier to tolerate, because it won't require patients to take companion medications with strong side effects.

    —The weekly number of new patients going on Sovaldi has been gradually slowing, from more than 2,900 in February and March to about 1,600-1,800 in late June and early July. Kleinrock said that could indicate that pent-up initial demand is giving way to steadier levels, or it could mean that insurers are limiting access to protect their budgets.

    Hepatitis C surpassed AIDS as a cause of death in the U.S. in 2007, claiming an estimated 15,000 lives that year. The illness is complex, with distinct virus types requiring different treatments. While it advances gradually, it can ultimately destroy the liver, and transplants average $577,000.

    The cost of a 12-week regimen of Sovaldi along with two companion medications that patients must also take is around $100,000. Competing regimens with other drugs cost in the mid- to high five figures, and some are far less effective and harder to tolerate. Hepatitis C is a public health concern, since the disease can be transmitted by contact with infected blood, by drug users sharing needles, and sometimes through sexual activity. Many people are unaware that they carry the virus. Health officials advise all baby boomers to get tested.

    At Mount Sinai Health System's liver clinic in New York City, patient advocate Angela Woody said Sovaldi has brightened the outlook for patients. But it takes effort to get insurance approval. "We have had to jump through a great deal of hoops," Woody said. "We have two patients who applied in January and did not actually go on the medication until April."

    Sovaldi's implications for Medicare and Medicaid costs have prompted rare bipartisan cooperation in Congress on a health care issue. Sens. Ron Wyden, D-Ore., and Charles Grassley, R-Iowa, are asking Gilead for a detailed explanation of its pricing. Wyden chairs the Finance Committee, which oversees health insurance programs, and Grassley is a veteran of drug safety investigations. The senators say their staffs found public documents that call into question Gilead's $84,000 price for a full course of Sovaldi treatment, for the most common type of hepatitis C.

    In 2011 filings with federal regulators, the company that originally developed Sovaldi estimated a treatment price of $36,000. That figure was developed during Gilead's negotiations to buy the original developer, Pharmasset. Gilead spokeswoman Amy Flood said the company has no comment. But Gilead vice president Gregg Alton recently addressed the issue at a public forum sponsored by the American Enterprise Institute.

    "To suggest that a cure for a disease like hepatitis C should be priced at $36,000 ... would put a huge disincentive on investing in cures for our industry," he said. Gilead took on most of the challenge — and risk — of getting government approval for Sovaldi, Alton added. He suggested another standard for measuring the value of Sovaldi, something called "cost-per-cure," that makes Sovaldi look like a bargain. The older hepatitis C treatments take longer and are less effective, and Alton estimated their cost-per-cure at somewhere between $150,000 and $200,000. Included are companion drugs that patients must also take. Sovaldi gets that down to $115,000 per cure, said Alton. "So it is actually, on a per-cure basis, much less costly."

    By The Associated Press, USNews.com/ July 29, 2014

    http://www.usnews.com/news/business...-000-pill-now-hepatitis-c-treatment-of-choice

    Newshawk Crew

    Author Bio

    Beenthere2Hippie
    BT2H is a retired news editor and writer from the NYC area who, for health reasons, retired to a southern US state early, and where BT2H continues to write and to post drug-related news to DF.

Comments

  1. TheBigBadWolf
    The damned injustice :mad:
    will be that patients in third world countries will be cut off from this treatment, the same as they are from cut off receiving adequate treatment for HIV infections.

    And Injecting Drug Users are by far the biggest group of people exposed to the HCV.


    Also on this topic please read: WHO hepatitis report and this here study about problems of funding Harm Reduction worldwide.

    Please let us know your thoughts on this treatment and what you believe could be done to provide this treatment globally.

    I'm interested in your views.
    BBW
  2. Staggered slash pipes
    I wonder if the price of the HCV medication Sovaldi along with two other unspecified meds also includes the price of frequent blood testing for viral loads and Infectious Disease Specialist care. Big business for the pharm, lab and hospitals. Likely working class heroes in the western world won't be able to afford with insurance nor will deserving people in third world countries be given top shelf care that exists. Will the pharmaceutical companies wait until it is pandemic before making it affordable?
To make a comment simply sign up and become a member!